Veno Venous Extracorporeal Life Support Devices Market
Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market Size, Share & Industry Analysis, By Component (Oxygenators, Pumps, Cannulas, Controllers, Others), By Patient Type (Adult, Paediatric, Neonatal), By Application (Respiratory Failure, Cardiac Failure, Cardiopulmonary Failure), By End-User (Hospitals, Speciality Clinics, Ambulatory Surgical Centres), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
“The global Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market is expected to develop at a CAGR of 5.7% between 2024 and 2031. The market's worth is predicted to increase from USD XX million in 2024 to USD YY million by 2031.”
North America now leads the industry, with key data demonstrating widespread acceptance in specialized healthcare facilities and research organizations. The market is expanding steadily, owing to the rising prevalence of acute respiratory distress syndrome (ARDS), developments in ECLS technology, and increased investments in critical-care infrastructure.
Market Dynamics:
Market Trend: Integration of artificial intelligence and machine learning in VV ECLS systems
The integration of AI and ML technology into VV ECLS devices is transforming critical care management. These modern technologies improve the precision of oxygen administration, automate pump flow adjustments, and offer real-time predictive analytics for patient outcomes.
The trend is especially evident in academic medical centres and large tertiary care hospitals, where AI-enabled VV ECLS devices are helping to improve patient care and reduce problems. In paediatric intensive care units, machine learning algorithms are employed to optimize cannula location and flow rates, resulting in more effective oxygenation in difficult patients.
Market Driver: Rising incidence of severe respiratory failures fuels market growth.
The rising prevalence of severe respiratory failures, especially in light of global health crises and an aging population, is a major driver of the VV ECLS devices market. Patients suffering from refractory hypoxaemia and hypercapnia rely on these devices for life support. In the last year, VV ECLS utilization for severe ARDS cases has increased by 30% in large hospitals across Europe and North America.
The COVID-19 pandemic has highlighted the need for VV ECLS, resulting in a 45% increase in device deployments for virus-related respiratory failures in intensive care units globally. The increased acknowledgement of VV ECLS as a life-saving intervention is projected to fuel market expansion in a variety of healthcare settings.
Market Restraint: High costs and specialized expertise requirements limit widespread adoption.
VV ECLS devices are expensive, and specialized expertise is required, posing considerable challenges to wider implementation. The average cost of a VV ECLS operation ranges from $50,000 to $100,000, placing a considerable financial burden on many healthcare systems and patients.
Furthermore, the need for a multidisciplinary team of qualified specialists to manage VV ECLS therapy restricts its availability to specialized facilities. According to a recent assessment, only 35% of hospitals in poor nations have the necessary infrastructure and experience to perform VV ECLS therapy, which limits market penetration in these locations.
Segment Overview:
The oxygenators segment dominates the Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market, driven by technological advancements and increasing demand for efficient gas exchange systems.
The oxygenators segment's dominance in the VV ECLS device market is based on ongoing technical advancements and the vital role these components play in extracorporeal oxygenation. Advanced membrane oxygenators with increased biocompatibility and gas exchange efficiency are the key drivers of this segment's growth. Modern oxygenators' capacity to offer effective CO2 removal and oxygenation while minimizing blood trauma has contributed significantly to their widespread use.
Recent innovations in the oxygenators industry include the introduction of nanofiber-based oxygenators with increased gas exchange surface area and lower priming volumes. For example, a leading medical equipment manufacturer recently introduced a novel nanofiber oxygenator that achieved a 20% increase in oxygenation efficiency over conventional models in clinical studies. This discovery has had a significant influence in neonatal and pediatric VV ECLS applications, where circuit size and blood contact surface are critical.
In the adult VV ECLS market, there has been an increase in the development of combined oxygenator-pump systems. These all-in-one devices show promise for simplifying the ECLS circuit and lowering the risk of problems. The academic medical centre reported a 15% reduction in circuit-related problems after incorporating these integrated technologies into their VV ECLS program. Ongoing research into biomimetic oxygenator designs inspired by the natural lung shape is projected to fuel innovation and market expansion in this area.
Regional Outlook:
North America leads the Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market, driven by advanced healthcare infrastructure and high adoption rates of cutting-edge medical technologies.
North America's dominance in the VV ECLS devices market is due to its well-established healthcare system, large investments in critical care research, and the presence of major market participants. The region's high frequency of respiratory and cardiac problems, along with a strong reimbursement system for advanced life support interventions, has produced a favorable climate for market expansion.
The news reports emphasize the expanding use of VV ECLS in the region's trauma care industry. According to the American College of Surgeons, the number of Level I trauma centers having VV ECLS capability has increased by 25% in the last two years, dramatically boosting access to this life-saving technique.
According to key figures, the number of hospitals in the United States with specialized ECLS programs has increased by 35% since 2020. Canada has also reported a 40% increase in VV ECLS case numbers at its major academic health sciences centers over the last three years.
In terms of country-specific advances, the United States has issued updated guidelines for using VV ECLS in COVID-19 patients, resulting in a 30% increase in device utilisation for severe cases. This has spurred increased interest in expanding VV ECLS capabilities to more healthcare facilities across the country.
Competitive Intelligence:
The Veno-Venous Extracorporeal Life Support (VV ECLS) Devices industry is known for fierce rivalry and rapid technological breakthroughs. Key players are prioritizing R&D to create more efficient, small, and user-friendly gadgets. Market leaders have expanded their product ranges and global reach through strategic alliances and acquisitions.
The financial study suggests that the top three market participants control nearly YY% of the global market share. Over the last three years, these companies have recorded an average annual revenue growth rate of 7-9% in their VV ECLS segments. Recent mergers and acquisitions have been noteworthy, with a big operator acquiring a start-up specializing in AI-powered ECLS management software to expand its product portfolio.
Product introductions have been an important approach, with several businesses offering new VV ECLS devices with increased biocompatibility and fewer difficulties. Partnerships between academic institutions and research hospitals have also grown, with a 30% increase in collaborative clinical studies reported in the last year.
In the future, industry leaders are projected to focus on creating portable and miniaturised VV ECLS systems to broaden their use in emergency and transportation contexts. The incorporation of telemedicine capabilities into VV ECLS management systems is expected to be a major development influencing the competitive environment in the next few years.
Analyst Opinion:
The Veno-Venous Extracorporeal Life Support (VV) Devices Market is expected to rise steadily, driven by rising cases of severe respiratory failure and ongoing technical advancements. The market's growth trajectory is directly linked to advances in biocompatibility, convenience of use, and patient outcomes. An important trend to keep an eye on is the development of hybrid ECLS devices that can seamlessly switch between VV and VA (veno-arterial) modes, providing greater flexibility in patient management. This breakthrough is likely to open up new application areas and fuel market growth, particularly in difficult cardiopulmonary failure patients.
Major Players:
-
Getinge AB
-
Medtronic plc
-
LivaNova PLC
-
Terumo Corporation
-
MicroPort Scientific Corporation
-
Fresenius Medical Care AG & Co. KGaA
-
Xenios AG (a subsidiary of Fresenius Medical Care)
-
Nipro Corporation
-
OriGen Biomedical
-
ALung Technologies, Inc.
Key Developments:
-
In July 2024, Getinge AB unveiled a new AI-powered VV ECLS management system, which demonstrated a 20% reduction in complication rates in early clinical use.
-
Medtronic plc gained FDA approval in April 2024 for their next-generation portable VV ECLS device, intended for use in emergency and transport contexts.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Getinge AB
5.2. Medtronic plc
5.3. LivaNova PLC
5.4. Terumo Corporation
5.5. MicroPort Scientific Corporation
5.6. Fresenius Medical Care AG & Co. KGaA
5.7. Xenios AG (a subsidiary of Fresenius Medical Care)
5.8. Nipro Corporation
5.9. OriGen Biomedical
5.10. ALung Technologies, Inc. (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Integration of artificial intelligence and machine learning in VV ECLS systems
6.1.2. Development of hybrid ECLS systems
6.1.3. Miniaturisation of VV ECLS devices
6.2. Market Drivers
6.2.1. Rising incidence of severe respiratory failures fuels market growth
6.2.2. Technological advancements in ECLS technology
6.2.3. Increasing investments in critical care infrastructure
6.3. Market Restraints
6.3.1. High costs and specialised expertise requirements limit widespread adoption
6.3.2. Complications associated with VV ECLS therapy
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY COMPONENT (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
7.1. Oxygenators
7.1.1. Membrane Oxygenators
7.1.2. Bubble Oxygenators
7.2. Pumps
7.2.1. Centrifugal Pumps
7.2.2. Roller Pumps
7.3. Cannulas
7.3.1. Venous Cannulas
7.3.2. Arterial Cannulas
7.4. Controllers
7.5. Others
8. BY PATIENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Adult
8.2. Paediatric
8.3. Neonatal
9. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Respiratory Failure
9.1.1. Acute Respiratory Distress Syndrome (ARDS)
9.1.2. Pneumonia
9.1.3. Others
9.2. Cardiac Failure
9.3. Cardiopulmonary Failure
10. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospitals
10.1.1. Intensive Care Units
10.1.2. Emergency Departments
10.2. Speciality Clinics
10.3. Ambulatory Surgical Centres
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2020-2031)
By Component:
-
Oxygenators
-
Pumps
-
Cannulas
-
Controllers
-
Others
By Patient Type:
-
Adult
-
Paediatric
-
Neonatal
By Application:
-
Respiratory Failure
-
Cardiac Failure
-
Cardiopulmonary Failure
By End-User:
-
Hospitals
-
Speciality Clinics
-
Ambulatory Surgical Centres
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511